Applied Genomics

Eyeing a commercial launch for Mammostrat in the fourth quarter of this year, Clarient highlighted publication of data further validating the test as “an aid for risk stratifying early stage hormone receptor-treated breast cancer patients."

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Applied Genomics is gearing up to launch a lung cancer diagnostic panel intended to help physicians make treatment decisions.

People In the News

Lai Named SVP of R&D at Gen-Probe, Jorge Leon Joins ParagonDx SAB, Strategic Diagnostics Hires Two Execs, and More.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.